Evidence map›Paper›PMID 31623625›Full record

SynthesisCardiovascular diabetology2019

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.

Ruth L Coleman, Charles A B Scott, Zhihui Lang, M Angelyn Bethel, Jaakko Tuomilehto, Rury R Holman

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05688332 (Comparison of Glycaemic and Cardiovascular Treatment Outcomes of Voglibose Versus Glibenclamide Added to Metformin in T2DM Patients in Zambia), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05688332 phase3unknown statusstarted 2023, after this paper: background citation

Comparison of Glycaemic and Cardiovascular Treatment Outcomes of Voglibose Versus Glibenclamide Added to Metformin in T2DM Patients in Zambia: An Open-label Randomised Clinical Trial

Ran2023Enrolled118Registered outcomes14Posted comparisons0ConditionsDiabetes Mellitus Type 2 Without ComplicationArmsGlibenclamide + Metformin, Voglibose + Metformin
PMID 34964875PMID 33651566PMID 32496728other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 4 countries.

Ruth L ColemanDiabetes Trials Unit, OCDEM, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, UK. ruth.coleman@dtu.ox.ac.uk.ORCID 0000-0002-5194-8550
Charles A B ScottDiabetes Trials Unit, OCDEM, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, UK.
Zhihui LangBayer Healthcare Company Ltd, Beijing, China.
M Angelyn BethelDiabetes Trials Unit, OCDEM, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, UK.
Jaakko TuomilehtoDepartment of Public Health Solutions, National Institute for Health and Welfare, 00271, Helsinki, Finland.
Rury R HolmanDiabetes Trials Unit, OCDEM, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, UK.
Churchill Hospital · GBBayer (China) · CNUniversity of Helsinki · FI

Funding

Department of Health
6 · The paper itself

Abstract

backgroundAlpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with respect to incident type 2 diabetes in individuals with impaired glucose tolerance (IGT), and CV outcomes in those with IGT or type 2 diabetes.

methodsWe used PubMed and SCOPUS to identify randomized controlled trials reporting the incidence of type 2 diabetes and/or CV outcomes that had compared AGIs with placebo in populations with IGT or type 2 diabetes, with or without established CV disease. Eligible studies were required to have ≥ 500 participants and/or ≥ 100 endpoints of interest. Meta-analyses of available trial data were performed using random effects models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes and CV outcomes.

resultsOf ten trials identified, three met our inclusion criteria for incident type 2 diabetes and four were eligible for CV outcomes. The overall HR (95% CI) comparing AGI with placebo for incident type 2 diabetes was 0.77 (0.67-0.88), p < 0.0001, and for CV outcomes was 0.98 (0.89-1.10), p = 0.85. There was little to no heterogeneity between studies, with I

conclusionsAllocation of people with IGT to an AGI significantly reduced their risk of incident type 2 diabetes by 23%, whereas in those with IGT or type 2 diabetes the impact on CV outcomes was neutral.

Indexed as

AgedCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleGlucose IntoleranceGlycoside Hydrolase InhibitorsHumansIncidenceMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTreatment OutcomeGlycoside Hydrolase InhibitorsAlpha glucosidase inhibitorCardiovascular diseaseImpaired glucose toleranceMeta-analysisType 2 diabetes

Identifiers

PMID31623625
PMCPMC6798440
OpenAlexW2981009876

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.